Trial Outcomes & Findings for A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder (NCT NCT02234011)
NCT ID: NCT02234011
Last Updated: 2017-05-12
Results Overview
Examining if ketamine is associated with a decrease in OCD symptoms as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) at completion of one treatment when compared to placebo (saline solution). The Y-BOCS measures OCD symptoms on a scale of 0-40, with higher numbers indicating greater severity of OCD symptoms. For this study, subjects had to have a Y-BOCS of greater than or equal to 18 in order to participate.
TERMINATED
PHASE2
1 participants
Baseline to Week 5
2017-05-12
Participant Flow
One subject completed the screening visit, but chose to withdraw from study due to time commitment required. Because this subject only completed a screening visit, she was never entered into the treatment arm of the study (which begins at the baseline visit).
Participant milestones
| Measure |
Treatment
No participants enrolled in treatment portion of study.
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Baseline to Week 5Population: One subject had a screening visit, but was never enrolled in the treatment portion and therefore never had any sort of treatment analysis performed on her data.
Examining if ketamine is associated with a decrease in OCD symptoms as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) at completion of one treatment when compared to placebo (saline solution). The Y-BOCS measures OCD symptoms on a scale of 0-40, with higher numbers indicating greater severity of OCD symptoms. For this study, subjects had to have a Y-BOCS of greater than or equal to 18 in order to participate.
Outcome measures
Outcome data not reported
Adverse Events
Treatment
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Brian Brennan, MD
McLean Hospital, Biological Psychiatry Laboratory
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place